

Publications in peer-reviewed journals (underlined: First or last author is from my group; ***van den Broek**: van den Broek is last author). See also <https://orcid.org/0000-0002-9489-3692>.

1. Faaber P, **van den Broek M**, Rijke TPM, Capel PJA, Berden JHM. 1985. Direct binding of monomeric anti-DNA antibodies to Raji cells. *Scand. J. Immunol.* 22:539-548.
2. **van den Broek M**, van den Berg WB, van de Putte LBA. 1986. Monoclonal anti-la antibodies suppress the flare up reaction of antigen-induced arthritis in mice. *Clin. exp. Immunol.* 66:320-330.
3. **van den Broek M**, van den Berg WB, van de Putte LBA. 1986. The role of MHC Class II antigens in the flare up reaction of antigen-induced arthritis in mice. *Agents & Actions* 19:328-330.
4. van den Elsen JHM, **van den Broek M**, Klasen IS, van den Berg WB. 1988. Stimulation of antigen-specific murine T cellclones in vitro with antigen pulsed adheherent cells fixed to a carrier. *J. Imm. Meth.* 112:15-22.
5. **van den Broek M**, van den Berg WB, van de Putte LBA, Severijnen AJ. 1988. Streptococcal cell wall-induced arthritis and flare reaction in mice induced by homologous and heterologous cell walls. *Am. J. Pathol.* 133:139-149.
6. **van den Broek M**, van den Berg WB, Arntz OJ, van de Putte LBA. 1988. Reaction of bacterium-primed murine T cells to cartilage components: a clue to the pathogenesis of arthritis? *Clin. Exp. Immunol.* 72:9-14.
7. **van den Broek M**, van den Berg WB, van de Putte LBA. 1988. The role of mast cells in antigen-induced arthritis in mice. *J. Rheumatol.* 15:544-551.
8. **van den Broek M**, van de Putte LBA, van den Berg WB. 1988. Crohn's disease associated with arthritis: a possible role for crossreactivity between gut bacteria and cartilage in the pathogenesis of arthritis. *Arthr. Rheum.* 30:1077-1079.
9. **van den Broek M**, van Bruggen MCJ, van de Putte LBA, van den Berg WB. 1988. T cell responses to streptococcal antigens in rats: Relation to susceptibility to streptococcal cell wall induced arthritis. *Cell. Immunol.* 116:216-229.
10. **van den Broek M**, van den Berg WB, van de Putte LBA. 1988. De rol van bakterien in de patogenese van artritis. *Ned. Tijdschrift voor Geneeskunde* 132:93.
11. **van den Broek M**, Hogervorst EJM, van Bruggen MCJ, van Eden W, van der Zee R, van den Berg WB. 1989. Protection against streptococcal cell wall induced arthritis by pretreatment with the 65 kD mycobacterial heat shock protein. *J. Exp. Med.* 170:449-466.
12. **van den Broek M**, van Bruggen MCJ, Stimpson SA, Severijnen AJ, van de Putte LBA, van den Berg WB. 1990. Flare up reaction of streptococcal cell wall-induced arthritis in Lewis and F344 rats: role of T lymphocytes. *Clin. Exp. Immunol.* 79:297-306.
13. van Bruggen MCJ, ***van den Broek M**, van de Putte LBA, van den Berg WB. 1991. Streptococcal cell wall-induced arthritis and adjuvant arthritis in F344 > Lewis and in Lewis > F344 bone marrow chimeras. *Cell. Immunol.* 136:278-290.
14. **van den Broek M**, van den Langerijt AJG, van Bruggen MCJ, Billingham MEJ, van den Berg WB. 1992. Treatment with anti.CD4 monoclonalantibodies induces long-term resistance to streptococcal cell wall-induced arthritis in rats. *Eur. J. Immunol.* 22:57-61.
15. **van den Broek M**, van Bruggen MCJ, Koopman JP, Hazenberg MP, van den Berg WB. 1992. Gut flora induces and maintains resistance to streptococcal cell wall-induced arthritis in F344 rats. *Clin. Exp. Immunol.* 88:313-317.
16. **van den Broek M**, de Heer E, van Bruggen MCJ, de Roo G, Euldering F, Hoedemaker P, van den Berg WB. 1992. Immunomodulation of streptococcal cell wall-induced arthritis: identification of regulatory T cell subsets and inflammatory cells by mercuric chloride and in vivo CD8.depletion. *Eur. J. Immunol.* 22:3091-3095.

17. Vreden SGS, **van den Broek M**, Oettinger MC, Verhave JP, Meuwissen JHET, Sauerwein RW. 1992. Cytokines inhibit the development of liver schizonts of the malaria parasite *Plasmodium berghei* in vivo. *Eur. J. Immunol.* 22:2271-2275.
18. Vreden SGS, Sauerwein RW, Verhave JP, van Rooijen N, Meuwissen JHET, ***van den Broek M**. 1993. Kupffer cell elimination enhances development of liver schizonts of *Plasmodium berghei* in rats. *Inf. Immunity* 61:1936-1939.
19. Vreden SGS, Blok WL, Sauerwein RW, Oettinger MC, Verhave JP, Meuwissen JHET, van der Meer JWM, ***van den Broek M**. 1995. Dietary fish oil supplementation inhibits *Plasmodium berghei* liver schizont development and reduces cytokine production capacity in rats. *Am. J. Trop. Med. Hyg.* 53:206-210.
20. Vreden SGS, **van den Broek M**, Oettinger CM, Boers W, van Rooijen N, Meuwissen JHET, Sauerwein R. 1995. Susceptibility to *Plasmodium berghei* infection in rats is modulated by the acute phase response. *Parasite Immunol.* 17:445-450.
21. Moskophidis D, Batteguay M, **van den Broek M**, Laine E, Hoffmann U, Zinkernagel RM. 1995. Role of virus and host variables in virus persistence or immunopathological disease caused by a non-cytolytic virus. *J. Gen. Virol.* 76:381-391.
22. **van den Broek M**, Müller U, Huang S, Aguet M, Zinkernagel RM. 1995. Anti viral defence in mice lacking type I and type II interferon receptors. *J. Virol.* 69:4792-4796.
23. **van den Broek M**, Boeije L, Swaak T, Smeenk R, Aarden L. 1995. Functional analysis of synovial fluid and peripheral blood T cells from patients with rheumatoid arthritis. *Rheum. Int.* 15:137-143.
24. **van den Broek M**, Kägi, D, Zinkernagel RM, Hengartner H. 1995. Perforin dependence of natural killer cell-mediated tumor control in vivo. *Eur. J. Immunol.* 25:3514-3516.
25. Groenink J, Spijker J, van den Herik.Oudijk E, Boeije L, Rook G, Smeenk RJT, Aarden LA, van de Winkel JGJ, ***van den Broek M**. 1996. On the role of the interaction between agalactosyl-IgG and Fc gamma-receptors. *Eur. J. Immunol.* 26:1404-1407.
26. **van den Broek M**, Kägi D, Ossendorp F, Toes R, Vamvakas S, Lutz W, Melief C, Zinkernagel RM, Hengartner H. 1996. Tumor surveillance in perforin-deficient mice. *J. Exp. Med.* 184:1781-1791.
27. **van den Broek M**, Spörri R, Even C, Plagemann PGW, Hänseler E, Hengartner H, Zinkernagel RM. 1997. Lactate dehydrogenase-elevating virus (LDV): Lifelong coexistence of virus and LDV-specific immunity. *J. Immunol. (The Cutting Edge)* 159:1585-1588.
28. Binder D, **van den Broek M**, Kägi D, Bluethmann H, Fehr J, Hengartner H, Zinkernagel RM. 1998. Irreversible bone marrow aplasia rescued by exhaustion of antiviral CD8+ T cells in persistent infection with Lymphocytic Choriomeningitis Virus. *J. Exp. Med.* 187:1903-1920.
29. Gallimore A, Schwarz K, **van den Broek M**, Hengartner H, Groettrup M. 1998. The proteasome inhibitor lactacystin prevents the generation of an endoplasmic reticulum leader-derived T cell epitope. *Molecular Immunology* 35:581-591.
30. Betz UAK, Bloch W, **van den Broek M**, Taga T, Kishimoto T, Addicks K, Rajewsky K, Müller W. 1998. Postnatally induced inactivation of gp130 in mice results in neurological, cardiac, hematopoietic, immunological, hepatic and pulmonary defects. *J. Exp. Med.* 188:1955-1965.
31. Grob P, Schijns VE, **van den Broek M**, Cox SP, Ackermann M, Suter M. 1999. Role of the individual interferon systems and specific immunity in mice in controlling systemic dissemination of attenuated pseudorabies virus infection. *J. Virol.* 73:4748-4754.
32. **van den Broek M**, Bachmann MF, Köhler G, Barner M, Escher R, Zinkernagel R, Kopf M. 2000. IL-4 and IL-10 antagonize IL-12-mediated protection against acute vaccinia virus infection with a limited role of IFN-gamma and nitric oxide synthetase. *J. Immunol.* 164:371-378.

33. Schwarz K, **van den Broek M**, de Giuli R, Seelentag W, Shastri N, Groettrup M. 2000. The use of LCMV-specific T cell hybridomas for the quantitative analysis of MHC class I restricted antigen presentation. *J. Immunol. Meth.* 237:199-202.
34. Schwarz K, de Giuli R, Kostka S, **van den Broek M**, Kim KB, Messerle M, Koszinowski UH, Crews CM, Kraft R, Groettrup M. 2000. The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or downregulate antigen presentation at nontoxic doses. *J. Immunol.* 164:6147-6157.
35. Schwarz K, **van den Broek M**, Kostka S, Kraft R, Soza A, Schmidtke G, Kloetzel P, Groettrup M. 2000. Overexpression of the proteasome subunits LMP₂, LMP₇, MECL.1, but not PA28alpha/beta, enhances the presentation of an immunodominant LCMV T cell epitope. *J. Immunol.* 165:768-778.
36. Wirth S, **van den Broek M**, Frossard C, Hugin A, Leblond I, Pircher H, Hauser C. 2000. CD8+ T cells secreting type 2 lymphokines are defective in protection against viral infection. *Cell. Immunol.* 202:13-22.
37. Khan S, de Giuli R, Schmidtke G, Bruns M, Buchmeier M, **van den Broek M**, Groettrup M. 2001. Cutting Edge: Neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. *J. Immunol.* 167:4801-4804.
38. Leung R, Thomson K, Gallimore A, Jones E, **van den Broek M**, Sierro S, Alsheikhly A, McMichael A, Rahemtulla A. 2001. Deletion of the CD4 silencer element supports a stochastic mechanism of thymocyte lineage commitment, *Nature Immunology* 2:1167-1173.
39. **van den Broek M**, Khan S, Schwarz K, de Giuli R, Diener P, Groettrup M. 2001. Immunoproteasomes largely replace constitutive proteasomes during an antiviral and antibacterial immune response in the liver. *J. Immunol.* 167:6859-6868.
40. Probst HC, Dumrese T, ***van den Broek M**. 2002. Cutting Edge: Competition for APC by CTL of different specificities is not functionally important during induction of antiviral responses. *J. Immunol.* 168:5387-5391.
41. Probst HC, Lagnel J, Kollias G, ***van den Broek M**. 2003. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. *Immunity*.18:713-721.
42. Probst HC, Tschanne K, Gallimore A, Martinic M., Basler M, Dumrese T, Jones E, ***van den Broek M**. 2003. Immunodominance of an antiviral cytotoxic T cell response is shaped by the kinetics of viral protein expression. *J. Immunol.* 171:5415-5422.
43. Basler M, Youhnovski N, **van den Broek M**, Prybylski M, Groettrup M. 2004. Immunoproteasomes downregulate the presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. *J. Immunol.* 173:3925-3934.
44. Probst HC, McCoy K, Okazaki T, Honjo T, ***van den Broek M**. 2005. Resting dendritic cells induce peripheral CD8+ T cell tolerance in vivo through PD-1 and CTLA-4. *Nature Immunology* 6:280-286.
45. Probst HC, ***van den Broek M**. 2005. Priming of CD8+ T cells by lymphocytic choriomeningitis virus depends on dendritic cells. *J. Immunol.* 174:3920-3924.
46. Probst HC, Tschanne K, Odermatt B, Schwendener R, Zinkernagel RM, ***van den Broek M**. 2005. Histological analysis of CD11c-DTR/GFP mice after in vivo depletion of dendritic cells. *Clin. Exp. Immunol.* 141:398-404.
47. Basta S, Stoessel R, Basler M, **van den Broek M**, Groettrup M. 2005. Cross-presentation of the long-lived lymphocytic choriomeningitis virus nucleoprotein does not require neosynthesis and is enhanced via heat shock proteins. *J. Immunol.* 175:796-805.
48. Lang K, Recher M, Navarini A, Freigang S, Harris N, **van den Broek M**, Odermatt B, Hengartner H, Zinkernagel R. 2005. Requirement for neutralizing antibodies to control bone marrow transplantation-associated persistent viral infection and to reduce immunopathology. *J. Immunol.* 175:5524-5531.

49. **van den Broek M**, Martinic M, Rülicke T, Huber C, Odermatt B, Reith W, Horvath E, Zellweger R, Fink K, Recher M, Eschli B, Hengartner H, Zinkernagel R. 2006. Functional CD8+ but not CD4+ T cell responses develop independent of thymic epithelial MHC. *Proc. Natl. Acad. Sci.* 39:14435-14440.
50. Schildknecht A, Miescher I, Yagita H, ***van den Broek M**. 2007. Priming of CD8+ T cell responses by pathogens typically depends on CD70-mediated interactions with DC. *Eur. J. Immunol.* 37:716-728.
51. Betts G, Twohig J, **van den Broek M**, Sierro S, Godkin A, Gallimore A. The impact of regulatory T cells in carcinogen induced sarcogenesis. 2007. *Br. J. Cancer* 18;96 (12):1849-1854.
52. ***van den Broek M**. 2007. Dendritic cells break bonds to tolerize. *Immunity* 27:544-546.
53. Schildknecht A, Welti S, Geuking MB, Hangartner L, ***van den Broek M**. Absence of cytotoxic T lymphocyte responses to early viral antigens facilitates viral persistence. 2008. *J. Immunol.* 180:3113-3121.
54. Knights AJ, Nuber N, Thomson CW, de la Rosa O, Jäger E, Tiercy JM, **van den Broek M**, Pascolo S, Knuth A, Zippelius A. Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. 2009. *Cancer Immunol. Immunother.* 58:325-338.
55. Keller AM, Schildknecht A, Xiao Y, **van den Broek M**, Borst J. Expression of costimulatory ligand CD70 on steady-state dendritic cells breaks CD8+ T cell tolerance and permits effective immunity. 2008. *Immunity* 29:1-13.
56. Schildknecht A, Probst HC, McCoy KD, Miescher I, Brenner C, Dino P, Leone D, Ueli Suter U, Pamela S. Ohashi PS, and ***van den Broek M**. Antigens expressed by myelinating glia cells induce peripheral cross-tolerance of endogenous CD8+ T cells. 2009. *Eur. J. Immunol.* 39:1-11.
57. Walch M, Rampini SK, Stoeckli I, Latinovic Golic S, Dumrese C, Sundstrom H, Vogetseder A, Marino J, Glauser DL, **van den Broek M**, Sander P, Groscurth P, Ziegler U. Involvement of CD252 (CD134L) and IL.2 in the expression of cytotoxic proteins in bacterial or viral activated human T cells. 2009. *J. Immunol.* 182:7569-7579.
58. Schildknecht A, Brauer S, Brenner C, Lahli K, Schild HJ, Sparwasser T, Probst HC, ***van den Broek M**. FoxP3⁺ regulatory T cells essentially contribute to peripheral CD8⁺ T cell tolerance induced by steady-state dendritic cells. 2010. *Proc. Natl. Acad. Sci. USA* 107:199-203.
59. Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, Fernandez M, Gattinoni L, Johnson S, Kreppel F, Kochanek S, **van den Broek M**, Radbruch A, Lévy F, Lambert PH, Siegrist CA, Restifo NP, Löhning M, Ochsenbein AF, Nabel GJ, Pinschewer DD. 2010. Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. *Nature Medicine* 16:339-345.
60. Walter A, Barysch MJ, Behnke S, Dziunycz P, Schmid B, Gnajatic S, Kristiansen G, Moch H, Knuth A, Dummer R, ***van den Broek M**. Cancer testis antigens and immunosurveillance in human cutaneous squamous cell and basal cell carcinomas. 2010. *Clinical Cancer Research* 16:3562-3570.
61. **van den Broek M**, von Boehmer L, Knuth A. 2010. Developments in cancer immunotherapy. *Dig. Dis.* 28:51-56
62. Nuber N, Curioni A, Matter C, Soldini D, Tiercy JM, von Boehmer L, Dummer R, Knuth A, ***van den Broek M**. 2010. Fine analysis of spontaneous MAGE-C1/CT7-specific immunity in melanoma patients. *Proc. Natl. Acad. Sci. USA* 107:15187-15192.
63. Moebius J, **van den Broek M**, Groettrup M, Basler M. 2010. Immunoproteasomes are essential for survival and expansion of T cells in virus-infected mice. *Eur. J. Immunol.* 40:3439-3449.
64. Peters R, Wolf M, **van den Broek M**, Nuvolone M, Dannenmann S, Stieger B, Rapold R, Konrad D, Rubin A, Bertino JR, Aguzzi A, Heikenwalder M, Knuth A. 2010. Efficient Generation of Multipotent Mesenchymal Stem Cells from Umbilical Cord Blood in Stroma-Free Liquid Culture. *PLOS One* 5:e215689.

65. Civenni G, Walter A, Kobert N, Mihic-Probst D, Belloni B, Seifert B, Moch H, Dummer R, **van den Broek M**, Sommer L. 2011. CD271-positive melanoma stem cells displaying neural crest stem cell features are associated with poor prognosis. *Cancer Research* 71:3098-3109.
66. Curioni-Fontecedro A, Nuber N, Mihic-Probst D, Seifert B, Soldini D, Dummer R, Knuth A, **van den Broek M**, Moch H. 2011. Expression of MAGE.C1/CT7 and MAGE.C2/CT10 predicts lymph node metastasis in melanoma patients. *PLOS One* 6:e21418.
67. von Boehmer L, Keller L, Mortezavi A, Provenzano M, Sais G, Hermanns T, Sulser T, Jungbluth A, Old L, Kristiansen G, **van den Broek M**, Moch H, Knuth A, Wild P. 2011. MAGE.C2/CT10 protein expression is an independent predictor of recurrence of prostate cancer. *PLOS One* 6:e21366.
68. Luethy A, Stenner F, Lohri C, Muller C, Samaras P, Steiner R, **van den Broek M**, Mischo A, Renner C, Knuth A, Ruegg C, Wenger RH, Zweifel M. 2011. Autologous Stem Cell Transplantation: Leukapheresis Product has anti-angiogenic Effects In Vivo Correlating with Neutrophil-derived VEGFR1. *Anticancer Res.* 31:3115-3124.
69. Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch H, Knuth A, von Boehmer L, ***van den Broek M**. 2011. γ -Radiation Enhances Immunogenicity of Cancer Cells by Increasing the Expression of Cancer-Testis Antigens *in vitro* and *in vivo*. *PLOS One*, e28217.
70. Audigé A, Hofer U, Dittmer U, **van den Broek M**, Speck RF. 2011. Evaluation of the immunomodulatory and antiviral effects of the cytokine combination IFN-alpha and IL-7 in the lymphocytic choriomeningitis virus and Friend retrovirus mouse infection models. *Viral Immunol.* 24(5):375-385.
71. Von Boehmer L, Draenert A, Jungraithmayr W, Inci I, Niklaus S, Boehler A, Hofer M, Stahel R, Soltermann A, **van den Broek M**, Weder W, Knuth A. 2012. Immunosuppression and lung cancer of donor origin after bilateral lung transplantation. *Lung Cancer*. 76:118-122.
72. Gupta A, Probst HC, Vuong V, Landshammer A, Muth S, Yagita H, Schwendener R, Behnke S, Prischy M, Knuth A, ***van den Broek M**. 2012. Radiotherapy promotes tumor-specific effector CD8⁺ T cells via DC activation. *J. Immunol.* 189:558-566.
73. Schliehe C, Bitzer A, **van den Broek M**, and Groettrup M. 2012. Stable antigen is most effective for eliciting CD8⁺ T-cell responses after DNA vaccination and infection with recombinant vaccinia virus *in vivo*. *J. Virol.* 86:9782-9793
74. Gupta A, Sharma A, von Boehmer L, Surace L, Knuth A, ***van den Broek M**. 2012. Radiotherapy supports protective tumor-specific immunity. *Oncolimmunology* 1:1610-1611.
75. Yoge N, Frommer F, Lukas D, Kautz.Neu K, Karram K, Ielo D, von Stebut E, Probst HC, **van den Broek M**, Riethmacher D, Birnberg T, Blank T, Reizis B, Ko Trn, Wiendl H, Jung S, Prinz M, Kurschus F, Waisman A. 2012. Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor⁺ Regulatory T Cells. *Immunity* 37:264-275.
76. Fischer E, Chaitanya K, Wüest T, Wadle A, Scott AM, **van den Broek M**, Schibli R, Bauer S, Renner C. 2012. Radioimmunotherapy of fibroblast activation protein positive tumors by rapidly internalizing antibodies. *Clinical Cancer Research* 15:6208-6218.
77. Gupta A, Nuber N, Esslinger E, Wittenbrink M, Treder M, Landshammer A, Noguchi T, Kelly M, Gnjatic S, Ritter E, von Boehmer L, Nishikawa H, Shiku H, Old L, Ritter G, Knuth A, ***van den Broek M**. 2013. A novel human-derived monoclonal antibody against NY-ESO-1 improves the efficacy of chemotherapy. *Cancer Immunology* 13:3-11.
78. Walter A, Schäfer M, Matter C, Urosevic.Maiwald M, Belloni B, Schönewolf N, Cecconi V, Kulig P, Dummer R, Bloch W, Werner S, Beer HD, Knuth A, ***van den Broek M**. 2013. Aldara activates two independent immune defense pathways. *Nature Communications* 4:1560 doi: 10.1038/ncomms2566.
79. Braumüller H, Wieder T, Fischer S, Brenner E, Hahn M, Alkhaled M, Schilbach K, Essmann F, Kneilling M, Griessinger C, Ranta F, Ullrich S, Mocikat R, Braungart K, Mehra T, Fehrenbacher B, **van den Broek M**,

Häring HU, Handgretinger R, Quintanilla-Martinez L, Fend F, Schaller M, Schulze-Osthoff K, Röcken M. 2013. Th1 cell cytokines drive cancer into senescence. *Nature* 494:361-365.

80. Dannenmann S, Thielicke J, Stöckli M, Matter C, von Boehmer L, Cecconi V, Hermanns T, Hefermehl L, Schraml P, Moch H, Knuth A, *van den Broek M. 2013. Myeloid cells promote progression of clear cell renal cell carcinoma. *Oncolimmunology* 2: eLocation ID: e23429.

81. von Boehmer L, Landshammer A, Bode P, Nuber N, Ritter G, Old L, Moch H, Jäger E, Knuth A, *van den Broek M. 2013. NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma. *Cancer Immunity* 13:12-18.

82. Sharma A, Bode B, Studer G, Moch H, Okoniewski M, Knuth A, von Boehmer L, *van den Broek M. 2013. Radiotherapy of human sarcoma promotes an intratumoral immune effector signature. *Clinical Cancer Research* 19:4843-4853.

83. Dannenmann S, Hermanns T, Bransi A, von Boehmer L, Matter C, Stevanovic S, Schraml P, Moch H, Knuth A, *van den Broek M. 2013. Spontaneous peripheral T cell responses towards the tumor-associated antigen Cyclin D1 in patients with clear cell renal cell carcinoma. *Cancer Immunology Research* 1:288-295.

84. Schuberth P, Hagedorn C, Jensen S, Gulati P, van den Broek M, Mischo A, Soltermann A, Jüngel A, Marroquin Belaunzarán O, Stahel R, Renner C, Petrusch U. 2013. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. *J. Transl. Med.* 11:187-197.

85. Nuber N, Curioni-Fontecedro A, Dannenmann SR, Matter C, von Boehmer L, Atanakovic D, Knuth A, *van den Broek M. 2013. MAGE-C1/CT7 spontaneously triggers a CD4⁺ T-cell response in multiple myeloma patients. *Leukemia* 27: 1767-1769.

86. Jakka G, Schuberth P, Thiel M, Held G, Stenner F, van den Broek M, Renner C, Mischo A, Petrusch U. 2013. Antigen-specific in vitro expansion of functional redirected NY-ESO-1-specific human CD8+ T cells in a cell-free system. *Anticancer Res.* 33:4189-4201.

87. Lohri C, Hutzli Schaltegger C, van den Broek M, Wenger R, Ruegg C, Fink D, Fehr M, Knuth A, Zweifel M. 2014. Neutrophil expression of ICAM1, CXCR1, and VEGFR1 in patients with breast cancer before and after adjuvant chemotherapy. *Anticancer Res.* 34:4693-4700.

88. Ruf M, Mittmann C, Hartmann A, Hermanns T, Poyet C, van den Broek M, Sulser T, Moch H, Schraml P. 2015. pVHL/HIF-regulated CD70 expression is associated with infiltration of CD27⁺ lymphocytes and increased serum levels of soluble CD27 in clear cell renal cell carcinoma. *Clinical Cancer Research* 21:890-898.

89. Surace L, Lysenko V, Fontana AO, Cecconi V, Janssen H, Bicvic A, Okoniewski M, Pruschy M, Dummer R, Neefjes J, Knuth A, Gupta A, *van den Broek M. 2015. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response. *Immunity* 42:767-777.

90. Marroquin Belaunzarán O, Kleber S, Schauer S, Hausmann M, Nicholls F, van den Broek M, Payeli S, Ciurea a, Milling S, Stenner F, Shaw J, Kollnberger S, Bowness P, Petrusch U, Renner C. 2015. HLA-B27-homodimer-specific antibody modulates the expansion of pro-inflammatory T-cells in HLA-B27 transgenic rats. *PLOS One* DOI:10.1371/journal.pone.0130811.

91. Bransi A, Salgado O, Beffinger M, Milo K, Silina K, Yagita H, Becher B, Knuth A, *van den Broek M. 2015. Rational combination of immunotherapy with clinical efficacy in mice with advanced cancer. *Cancer Immunology Research* 3:1279-1288.

92. Surace L, Scheifinger N, Gupta A, *van den Broek M. 2015. Radiotherapy supports tumor-specific immunity by acute inflammation. *Oncolimmunology*, DOI: 10.1080/2162402X.2015.1060391.

93. Surace L, Guckenberger M, *van den Broek M. 2015. Radiation holidays stimulate tumor immunity. *Oncotarget* 6:15716-15717.

94. Ohs I, van den Broek M, Nussbaum K, Münz C, Arnold S, Quezada S, Tugues S, Becher B. 2016.

Interleukin-12 bypasses common gamma-chain signaling in emergency natural killer cell lymphopoiesis. Nature Communications 7:13708. doi: 10.1038/ncomms13708.

95. Chevrier S, Levine JH, Zanotelli V, Silina K, Schulz D, Bacac M, Ries C, Ailles L, Jewett MAS, Mich H, **van den Broek M**, Beisel C, Stadler MB, Gedye C, Reis B, Pe'er D, Bodenmiller B. 2017. An immune atlas of renal carcinoma links phenotypes to immunosuppression and clinical features. Cell. 169:736-749.
96. Curioni-Fontecedro A, Ickenberg C, Franzen D, Rogler G, Burger IA, ***van den Broek M**. 2017. Diffuse pseudoprogression in a patient with metastatic non-small cell lung cancer treated with Nivolumab. Annals of Oncology 28:2040-2041. DOI: 10.1093/annonc/mdx233
97. Willrodt AH, Beffinger M, Vranova M, Protsyuk D, Schuler B, Heikenwälder M, **van den Broek M**, Borsig L, Halin Winter C. 2017. Stromal expression of activated leukocyte cell adhesion molecule (ALCAM) promotes lung tumor growth and metastasis. Am. J. Pathol. 187:2558-2569.
98. Posch F, Silina K, Leibl S, Mündlein A, Moch H, Siebenhüner A, Pestalozzi B, Riedl J, Stotz M, Szkandera J, Stöger H, Pichler M, Stupp R, **van den Broek M**, Schraml P, Gerger A, Petrusch U, Winder T. 2017. Maturation of tertiary lymphoid structures predicts the risk for recurrence in stage II and III colorectal cancer. Oncoimmunology, 7(2):e1378844. DOI: 10.1080/2162402X.2017.1378844
99. Silina K, Soltermann A, Movahedian Attar F, Casanova R, Uckley Z, Thut H, Isajevs S, Cheng S, Curioni-Fontecedro A, Foukas P, Levesque M, Moch H, Linē A, ***van den Broek M**. 2018. Germinal centers determine the prognostic relevance of tertiary lymphoid structures and are impaired by corticosteroids in lung squamous cell carcinoma. Cancer Res. 78:1308-1320.
100. Zimmerli D, Cecconi V, Valenta T, Hausmann G, Cantù C, Restive G, Hafner J, Basler K, ***van den Broek M**. 2018. WNT-ligands control initiation and progression of human papilloma-virus-driven squamous cell carcinoma. Oncogene, 37:3753-3762.
101. Beffinger M, Tallón de Lara P, Tugues S, Vermeer M, Montagnolo Y, Ohs I, Cecconi V, Lucchiari G, Gagliardi A, Misljencevic N, Sutton J, Spörri R, Becher B, Gupta A, ***van den Broek M**. 2018. CSF1R-dependent monocytes are required for NK-mediated control of metastasis. J Clin Invest insight, 3(10):e97792.
102. Arnold I, Artola-Boran M, Tallón de Lara P, Kyburz A, Taube C, Ottemann K, **van den Broek M**, Yousefi S, Simon H-U, Müller A. 2018. Eosinophils suppress Th1 responses and restrict bacterially induced gastrointestinal inflammation. J. Exp Med. 215:2055-2072.
103. Tallón de Lara P, Cecconi V, Hiltbrunner S, Yagita H, Friess M, Bode B, Schmitt-Opitz I, Vrugt B, Weder W, Stolzmann P, Felley- Bosco E, Stahel R, Tischler V, Soldini D, Moch H, * Curioni-Fontecedro A, ***van den Broek M**. 2018. Gemcitabine acts in synergy with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients. Clinical Cancer Res. 24:6345-6354.
104. Tugues S, Amorim A, Spath S, Martin-Blondel G, Schreiner B, De Feo D, Lutz M, Guscetti F, Apostolova P, Haftmann C, Hasselblatt P, Núñez NG, Hottiger MO, **van den Broek M**, Manz MG, Zeiser R, Becher B. 2018. GM-CSF-licensed myeloid cells mediate graft-vs-host disease uncoupling immunopathology from the graft-vs-leukemia effect. Science Translational Medicine. 10, eaat8410.
105. Silina K, Burkhardt C., Casanova R., Solterman A., ***van den Broek M**. 2018. A Quantitative Pathology Approach to Analyze the Development of Human Cancer-Associated Tertiary Lymphoid Structures. In: Dieu-Nosjean MC. (eds) Tertiary Lymphoid Structures. Methods in Molecular Biology, vol 1845. Humana Press, New York, NY.
106. Wagner J, Rapsomaniki MA, Chevrier S, Anzeneder T, Langwieder C, Dykgers A, Rees M, Ramaswamy A, Muenst S, Soysal SD, Jacobs A, Windhager J, Silina K, **van den Broek M**, Dedes KJ, Rodriguez Martinez M, Weber WP, Bodenmiller. 2019. A single-cell atlas of the tumor and immune ecosystem of human breast cancer. Cell. 177:1330-1345.

107. Cossarizza A. ... **van den Broek M** ... Zychlinsky A. 2019. Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). *Eur. J. Immunol.* 49:1457-1973.
108. Schadt L, Sparano C, Schweiger N, Silina K, Cecconi V, Lucchiari G, Guggisberg E, Saba S, Nascakova Z, Barchet W, ***van den Broek M**. 2019. Cancer cell-intrinsic cGAS expression mediates tumor immunogenicity. *Cell Rep.* 29:1236-1248.
109. Myburgh R, Kiefer J, Russkamp N, Magnani C, Nunez N, Simonis A, Pfister S, Wilk m, McHugh D, Friemel J, Mueller A, Becher B, Münz C, **van den Broek M**, Neri D, Manz M. 2020. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. *Leukemia*. doi.org/10.1038/s41375-020-0818-9.
110. van Dijk N, Gil-Jimenez A, Silina K, Hendrickson K, Smit L, de Feijter JM, van Montfoort M, van Rooijen C, Peters D, Broeks A, van der Poel H, Bruining A, Lubeck Y, Sikorska K, Boellaard T, Kvistborg P, Vis DJ, Hooijberg E, Schumacher TN, **van den Broek M**, Wessels L, Blank CU, van Rhijn BW, van der Heijden MS. 2020. Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer. *Nature Med.* 26:1839-1844.
111. Tallón de Lara P, Castañón H, Vermeer M, Núñez N, Silina K, Sobottka B, Urdínez J, Cecconi V, Yagita H, Movahedian Attar F, Hiltbrunner S, Glarner I, Moch H, Tugues S, Becher B, ***van den Broek M**. 2021. CD39⁺PD-1⁺CD8⁺ T-cells mediate metastatic dormancy in breast cancer. *Nature Communications*. 12:769. doi.org/10.1038/s41467-021-21045-2.
112. Lelios I, Stifter SA, Cecconi V, Petrova E, Lutz M, Cansever D, Utz SG, Becher B, ***van den Broek M**, Greter M. 2021. Monocytes promote UV-induced epidermal carcinogenesis. *Eur. J. Immunol.* 51:1799-1808. http://dx.doi.org/10.1002/eji.202048841.
113. Sobottka B, Lorch A, Silina K, **van den Broek M**, Moch H. 2021. Renal cell carcinoma pathology in 2021: New need for renal cancer immune profiling. *Current Opinion Urol.* 31:228-235.
114. Ducimetière L, Lucchiari G, Litscher G, Nater M, Heeb L, Núñez N, Wyss L, Burri D, Vermeer M, Gschwend J, Moor A, Becher B, ***van den Broek M**, Tugues S. 2021. Conventional NK cells and tissue resident ILC1s join forces to control liver metastasis. *Proc. Natl. Acad. Sci. USA*. https://doi.org/10.1073/pnas.2026271118.
115. Schneider MA, Beffinger MM, Pantelyushin S, Linecker M, Roth L, Lehmann K, Ungethüm U, Kobold S, Graf R, **van den Broek M**, vom Berg J, Gupta A, Clavien PA. 2021. Peripheral serotonin dampens tumor-specific immunity via induction of PD-L1 expression. *Science Translational Medicine*. 13, eabc8188.
116. van Dijk N, Gil-Jimenez A, Silina K, van Montfoort ML, Einerhand S, Jonkman L, Voskuilen C, Peters D, Sanders J, Lubeck Y, Broeks A, Hooijberg E, Vis DJ, van den Broek M, Wessels LFA, van Rhijn BWG, van der Heijden MS. 2021. The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer. *Frontiers in Immunology*. https://doi.org/10.3389/fimmu.2021.793964.
117. Tallón de Lara P, Castañón H, Sterpi M, ***van den Broek M**. 2022. Anti-metastatic defense by CD8⁺ T cells. *Trends in Cancer* 8:145-157. https://doi.org/10.1016/j.trecan.2021.10.006
118. Silina K, Pagliarulo F, Cheng PF, Brugger L, Dijk N, van der Heijden MS, Levesque MP, ***van den Broek M**. 2022. Molecular, immunological, and clinical features associated with lymphoid neogenesis in muscle invasive bladder cancer. *Frontiers in Immunology*. https://doi.org/10.3389/fimmu.2021.793992.